ASCO Presentations Highlight Findings from Clinical Trials with ArQule's (ARQL) c-MET Inhibitor, ARQ 197
More News related to ARQL
- ArQule (ARQL) Posts Q3 Loss of $0.18, Beats Estimates; Reaffirms Guidance
- ArQule Announces Third Quarter Fiscal 2009 Results
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- ArQule, Inc. to Report Third Quarter 2009 Financial Results on Thursday, November 5, 2009
- ArQule, Inc. to Present at Oppenheimer 20th Annual Healthcare Conference on November 3, 2009
Investigators presented data at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) from four clinical trials with ARQ 197, an inhibitor of the c-MET receptor tyrosine kinase under development by ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo Co., Ltd.
"Key findings from these studies with ARQ 197 include clinical benefit shown in preliminary results from an ongoing Phase 2 trial in patients with MiT-associated tumors, evidence of prolonged stable disease among patients with advanced metastatic non-small cell lung cancer (NSCLC) in a Phase 1 combination with erlotinib, and the observation of an anti-angiogenic effect in a Phase 1 trial among patients with metastatic solid tumors that supports previously presented clinical and pre-clinical data," said Paolo Pucci, chief executive officer of ArQule.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
